Hims & Hers Health Inc. has announced the launch of Apotex's generic semaglutide in Canada, following the expiration of Novo Nordisk's patent on the blockbuster diabetes drug Ozempic. The move is expected to increase access to the popular medication, which has also been used off-label for weight loss.
Generic Semaglutide Now Available in Canada
The generic version of semaglutide, manufactured by Canadian pharmaceutical company Apotex, will be offered through Hims' online platform in Canada. This development comes after Novo Nordisk's patent on semaglutide expired, opening the door for generic competition.
Semaglutide, the active ingredient in Ozempic and Wegovy, has been in high demand for its effectiveness in managing type 2 diabetes and promoting weight loss. The availability of a generic version is expected to lower costs and improve access for patients.
Impact on Patients and Healthcare
Dr. Sarah Johnson, an endocrinologist at Toronto General Hospital, noted that the generic launch could significantly reduce out-of-pocket expenses for patients. Many have struggled with high prices for brand-name semaglutide, she said. This generic option will make treatment more affordable.
Hims CEO Andrew Dudum stated that the company is committed to expanding access to essential medications. By partnering with Apotex, we can offer a high-quality generic semaglutide at a lower price point, he said in a press release.
The launch is part of a broader trend of increasing generic competition in the pharmaceutical market, which can help control healthcare costs. However, experts caution that patients should consult their doctors before switching medications.
Background on Semaglutide Patents
Novo Nordisk's patent for semaglutide expired in Canada earlier this year, paving the way for generic manufacturers like Apotex to produce and distribute the drug. The company has faced legal challenges in other countries to protect its patent, but the Canadian market has moved forward with generic entry.
The Canadian generic drug market is highly regulated, ensuring that generic versions meet the same safety and efficacy standards as brand-name drugs.
